smartcybers786@gmail.com 
Pakistani Prime Minister Shehbaz Sharif speaks at the 77th session of the United Nations General Assembly (UNGA) at U.N. headquarters on September 23, 2022 in New York City. — AFP
#orders #review #medicine #prices #public #outcry
ISLAMABAD: Prime Minister Shahbaz Sharif has directed the Drug Regulatory Authority of Pakistan (DRAP) to confirmed that it was independent of its public tolerance for the public tolerance.
Working faster on the instructions of the Prime Minister, the World Health Organization (WHO) office in Islamabad has been approached to conduct a comprehensive analysis of the policy, which was presented during the 2024 caretaker regime led by Anwar -ul -Haq Kakar.
The WHO has been officially asked to examine the results of the unlawful pricing on access to patients and recommend corrective measures.
“Patients and health care officials have an increasing incompetence about the unprecedented increase in pharmaceutical prices,” a senior health official told The News. “The Prime Minister wants a neutral, technical review of a neutral, technical review framework and its real world results.”
Federal Minister for Health Mustafa Kamal and Minister of State for Health Malik Mukhtar Ahmad Bharat have also taken notice of the crisis and has sought a detailed report from the drop on how much price of unnecessary drugs has increased during the last year, and pharmaceutical companies have offered for these hiking. “If a person’s monthly medicine cost has increased from Rs 800 to Rs 2,200 or even Rs 2,500, what is justified?” Talking to this news, Dr. Mukhtar asked. “We have asked the drop CEO to compile this data and tell them what they are increasing.”
Initially, it was initially developed to tackle the chronic shortage of essential drugs and to attract multinational firms to accommodation of inflation and prices according to market forces. However, health officials, members of the assembly and civil society believe that the policy has been unbeaten, some pharmaceutical firms travel on prices on a monthly or weekly basis.
Industry data supports these concerns. According to IQVIA, Pakistan’s pharmaceutical market overturned Rs.049 trillion by March 2025a, which increased the rupee terms by 20.62 %. However, the sales of the unit increased by only 3.63 %, confirming that the growth of the pharmaceuticals is almost completely run by the increase in prices rather than increasing the consumption of the drug. The market was only due to a change in prices. National firms sold 2.91 billion units, with a slight growth of 4.98 %, while multinational companies saw a decline in volume but sales prices saw a sharp rise, which led to the increase in prices, not demand, how to eliminate revenue.
Even basic over -anti -drug drugs like paracetamol have seen volatility in prices.
The WHO’s review is expected to examine the results of both the economic and health of the unlawful prices. The O -drop official acknowledged the urgent need for the matter and said the regulator was “fully cooperating” with whom to ensure a comprehensive and independent review. “The market cannot be fully disorganized, especially as the medicine of something is especially important as the medicine. This review will help set a course toward pricing which is both fair and sustainable.”
Although pharmaceutical companies argue that the need for irregularities to maintain supply chains and maintain a hedge against inflation, now federal policy makers face increasing pressure to curb free prices, and they do not make sure that they are not sure.
